Amide Compound Aβ Aggregation Inhibition Metabolic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pentapeptides with Aβ aggregation inhibitory activity have weak effects and low metabolic stability, making them inadequate for effectively preventing or treating Alzheimer's disease caused by amyloid deposition.
Innovation Solution
Development of an amide compound represented by a specific formula or its salt, which exhibits superior Aβ aggregation inhibitory activity, useful as a prophylactic or therapeutic agent for Alzheimer's disease and other amyloid deposition-related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a pentapeptide consisting of naturally occurring amino acids is used as an Aβ aggregation inhibitor, then it shows some aggregation inhibitory activity, but its metabolic stability is low and the activity is very weak
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure from a natural pentapeptide to a synthetic amide compound with specific molecular formula (I). The compound features a pyridine or pyrimidine ring core with specific substituent patterns (R1, R2, R3 groups) that fundamentally alter its metabolic stability while maintaining or enhancing Aβ aggregation inhibition. This structural parameter transformation resolves the contradiction by achieving both high activity and metabolic stability simultaneously.
Solution Approach 2:
The invention creates a composite molecular structure combining a heterocyclic core (pyridine or pyrimidine ring) with specific aromatic or aliphatic substituent groups. This composite structure integrates the aggregation-inhibiting properties of peptide-mimicking moieties with the metabolic stability of small-molecule heterocycles, thereby achieving both high Aβ aggregation inhibition and improved metabolic stability that neither component alone could provide.
2Reliability
If a pentapeptide is used as an Aβ aggregation inhibitor, then it can be administered, but its Aβ aggregation inhibitory activity is very weak and insufficient for effective treatment
Solution Approach 1:
The patent dramatically improves therapeutic effectiveness by changing the molecular parameters from a 5-amino acid peptide to a small-molecule amide compound with specific heterocyclic core and substituent architecture. This parameter transformation results in significantly enhanced Aβ aggregation inhibitory activity, converting a weak therapeutic agent into a highly effective treatment for Alzheimer's disease and related conditions.
Solution Approach 2:
The invention extracts and amplifies the essential aggregation-inhibiting functionality from the pentapeptide structure while removing the limiting factors (peptide backbone, natural amino acid constraints). By isolating and optimizing the key pharmacophore elements into a small-molecule amide framework, the patent achieves potent Aβ aggregation inhibition with much higher therapeutic effectiveness than the original pentapeptide.
Data Source
AI summary
Provided is a novel compound which has an excellent Aβ aggregation inhibitory effect and is useful as a pharmaceutical. An amide compound represented by the formula (1) or a salt thereof, wherein Z represents CH or N; A and B are the same or different and each represents —CH2—, —O—, —S—, or —NH—; R1 and R2 are the same or different and each represents a branched alkyl group, a branched alkenyl group, an optionally substituted aromatic hydrocarbon group, an optionally substituted aralkyl group, an optionally substituted cycloalkyl group, or an optionally substituted aromatic heterocyclic group; and R3 represents a branched alkyl group, a branched alkenyl group, an optionally substituted cycloalkyl group, or an optionally substituted aralkyl group.